

# Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer

Srinivas R. Viswanathan<sup>1,2,3</sup>, Marina F. Nogueira<sup>1,2,12</sup>, Colin G. Buss<sup>4,5,12</sup>, John M. Krill-Burger<sup>2</sup>, Mathias J. Wawer<sup>6</sup>, Edyta Malolepsza<sup>2,7</sup>, Ashton C. Berger<sup>1,2</sup>, Peter S. Choi<sup>1,2,3</sup>, Juliann Shih<sup>1,2</sup>, Alison M. Taylor<sup>1,2,3</sup>, Benjamin Tanenbaum<sup>1,2</sup>, Chandra Sekhar Pedomallu<sup>1</sup>, Andrew D. Cherniack<sup>1,2</sup>, Pablo Tamayo<sup>1,2,8</sup>, Craig A. Strathdee<sup>2</sup>, Kasper Lage<sup>2,7</sup>, Steven A. Carr<sup>2</sup>, Monica Schenone<sup>1,2</sup>, Sangeeta N. Bhatia<sup>2,3,4,5,9,10,11</sup>, Francisca Vazquez<sup>2</sup>, Aviad Tsherniak<sup>1,2</sup>, William C. Hahn<sup>1,2,3</sup> and Matthew Meyerson<sup>1,2,3\*</sup>

**Functional redundancy shared by paralog genes may afford protection against genetic perturbations, but it can also result in genetic vulnerabilities due to mutual interdependency<sup>1–5</sup>. Here, we surveyed genome-scale short hairpin RNA and CRISPR screening data on hundreds of cancer cell lines and identified *MAGOH* and *MAGOHB*, core members of the splicing-dependent exon junction complex, as top-ranked paralog dependencies<sup>6–8</sup>. *MAGOHB* is the top gene dependency in cells with hemizygous *MAGOH* deletion, a pervasive genetic event that frequently occurs due to chromosome 1p loss. Inhibition of *MAGOHB* in a *MAGOH*-deleted context compromises viability by globally perturbing alternative splicing and RNA surveillance. Dependency on *IPO13*, an importin- $\beta$  receptor that mediates nuclear import of the *MAGOH*/B-Y14 heterodimer<sup>9</sup>, is highly correlated with dependency on both *MAGOH* and *MAGOHB*. Both *MAGOHB* and *IPO13* represent dependencies in murine xenografts with hemizygous *MAGOH* deletion. Our results identify *MAGOH* and *MAGOHB* as reciprocal paralog dependencies across cancer types and suggest a rationale for targeting the *MAGOHB*-*IPO13* axis in cancers with chromosome 1p deletion.**

The systematic integration of data from genomic characterization and genetic screening of cancer cell lines can identify gene dependencies induced by specific somatic alterations and inform the development of targeted therapeutics. For example, several studies have shown that inactivation of specific driver or passenger genes may confer dependency on functionally redundant paralogs<sup>2,3,10–13</sup>. Paralog dependencies have also emerged as important targets in recent genome-scale functional genomic screens<sup>4,5</sup>, underscoring the importance of further characterizing this class of cancer vulnerabilities.

To systematically identify paralog dependencies that may represent attractive cancer targets, we analyzed data from pooled, genome-scale short hairpin RNA (shRNA) screening of 501 cancer cell lines<sup>5,14</sup>. We determined the correlation between a dependency

on a gene<sup>5</sup> and loss of function of its paralog across 10,287 paralog pairs (Supplementary Fig. 1; Supplementary Note). We identified 167 genes for which dependency was significantly correlated with loss of a paralog (1.6% of paralog test pairs at  $q < 0.05$ ), including many previously reported paralog dependencies (for example, *ARID1B* dependency with *ARID1A* inactivation<sup>10</sup>, *SMARCA2* dependency with *SMARCA4* inactivation<sup>11</sup>, *UBC* dependency with *UBB* inactivation<sup>5</sup>, and *FERMT1* dependency with *FERMT2* inactivation<sup>5</sup>). However, of these 167 paralog dependency pairs, only 7 were ‘symmetric’, in which dependency for each of the genes in the pair was significantly correlated with inactivation of its partner paralog (Fig. 1a,b; Supplementary Table 1). A similar analysis of data from genome-scale CRISPR screening of 341 cell lines<sup>15</sup> identified 125 significant paralog dependencies (1.4% of paralog test pairs at  $q < 0.05$ ), of which 7 pairs were symmetric (Supplementary Table 2; Supplementary Note). Paralog genes arise via ancestral duplication events and may functionally diverge over time<sup>1,16</sup>. Symmetric paralog pairs likely share complete functional redundancy, making them particularly attractive targets for ‘collateral lethality’ strategies<sup>2</sup>. An enrichment for RNA-splicing related genes was noted among symmetric, but not asymmetric, paralog pairs in the shRNA and CRISPR screening datasets (Supplementary Table 3), suggesting that redundant essentiality may be exploited to target splicing-related pathways.

One symmetric paralog pair was shared between the shRNA and CRISPR datasets: *MAGOH*-*MAGOHB*; a second pair, *FUBP1*-*KHSRP*, was highly significant for symmetry in the shRNA data and borderline significant in the CRISPR dataset ( $q_1 = 0.0547$ ) (Fig. 1a,b; Supplementary Fig. 1; Supplementary Tables 1 and 2)<sup>15</sup>. We focus here on validation of the former pair. *MAGOH* and *MAGOHB* encode core members of the exon–junction complex (EJC), a multiprotein complex that is deposited on messenger RNAs at the time of splicing and that mediates diverse downstream processes including mRNA transport, stability, and nonsense-mediated decay (NMD)<sup>6,17</sup>.

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. <sup>2</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA. <sup>3</sup>Harvard Medical School, Boston, MA, USA. <sup>4</sup>Harvard-MIT Department of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Boston, MA, USA. <sup>5</sup>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>6</sup>Chemical Biology and Therapeutics Science Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA. <sup>7</sup>Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. <sup>8</sup>UCSD Moores Cancer Center and Department of Medicine, University of California, San Diego, La Jolla, CA, USA. <sup>9</sup>Howard Hughes Medical Institute, Chevy Chase, MD, USA. <sup>10</sup>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>11</sup>Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. <sup>12</sup>These authors contributed equally: Marina F. Nogueira, Colin G. Buss. \*e-mail: [matthew\\_meyerson@dfci.harvard.edu](mailto:matthew_meyerson@dfci.harvard.edu)

Using both shRNA and CRISPR technologies, we individually validated *MAGOHB* dependency in the setting of *MAGO*H loss, as well as *MAGO*H dependency in the setting of *MAGOHB* loss. Furthermore, in a cell line without hemizygous deletion of either paralog, knockdown of either *MAGO*H or *MAGOHB* individually was tolerated, but the combination was lethal (Supplementary Fig. 2). We noted that *MAGOHB* dependency in the setting of *MAGO*H inactivation was particularly pronounced based on (1) effect size (log-fold difference in *MAGOHB* dependency between *MAGO*H-inactivated and non-*MAGO*H-inactivated cell lines) and (2) *MAGOHB* scoring as a robust 6 $\sigma$  differential dependency (having a dependency score in some cell lines greater than six standard deviations below its mean dependency score across all cell lines) in both the RNA interference (RNAi) and CRISPR screening data. We therefore sought to further characterize *MAGOHB* dependency in the setting of *MAGO*H loss.

*MAGOHB* was the top differential dependency in cells with hemizygous deletion of *MAGO*H (Fig. 1c; Supplementary Tables 4 and 5; Supplementary Note) and dependency on *MAGOHB* was predicted by low expression of *MAGO*H, consistent with the notion that hemizygous deletion of *MAGO*H leads to its decreased expression (Supplementary Fig. 3). shRNA-mediated knockdown of *MAGOHB* led to a decrease in cell viability and colony-forming capacity in three *MAGO*H-deleted cell lines, but not in control cell lines euploid for *MAGO*H (Fig. 1d,e; Supplementary Fig. 4). Ectopic expression of *MAGO*H in an *MAGO*H-deleted cell line fully rescued *MAGOHB* dependency, indicating that *MAGOHB* dependency in *MAGO*H-deleted cells is solely due to *MAGO*H loss, and consistent with complete functional redundancy between these paralogs<sup>8</sup> (Fig. 1f; Supplementary Fig. 4). CRISPR/Cas9-mediated deletion of *MAGO*H in a cell line with two copies of *MAGO*H also conferred *MAGOHB* dependency (Supplementary Figs. 5 and 6).

To assess the clinical contexts in which these dependencies might be exploited, we next surveyed the frequency of *MAGO*H and *MAGOHB* loss in tumor cohorts from The Cancer Genome Atlas (TCGA). We observed pervasive hemizygous *MAGO*H loss across tumor types (frequency of 21% (1,675 of 8,009) in the entire TCGA dataset, and >50% in multiple tumor types). Moreover, *MAGO*H deletion most frequently occurs as a result of arm-level deletion of chromosome 1p across human tumors (Fig. 1g; Supplementary Table 6). We confirmed that chromosome 1p-deletion status correlates with *MAGOHB* dependency in the genome-scale CRISPR screening data (Supplementary Fig. 7). In the context of neuroblastoma—where 1p deletion is a hallmark event in a subset of tumors<sup>18</sup>—*MAGOHB* knockdown was lethal in a 1p-deleted, but not a 1p-neutral, cell line (Supplementary Fig. 7). *MAGOHB* is located on chromosome 12p, an arm also recurrently lost across tumor types, albeit with markedly lower frequency than chromosome 1p (Supplementary Fig. 8). Analysis of genome-scale CRISPR screening data confirmed a reciprocal dependency on *MAGO*H in the setting of chromosome 12p deletion. Interestingly, we also observed mutual exclusivity between chromosome 1p and chromosome 12p codeletion in many tumor types, suggesting that concurrent loss of both *MAGO*H and *MAGOHB* may be poorly tolerated (Supplementary Fig. 8). We conclude that *MAGO*H and *MAGOHB* represent potential vulnerabilities in large, genetically defined subsets of tumors.


*MAGO*H and *MAGOHB* constitute core components of the EJC<sup>8</sup>; EJC deposition at exon–exon junctions allows transcripts containing premature termination codons to be identified and targeted for degradation via NMD<sup>6,17</sup>. We therefore hypothesized that *MAGOHB* inhibition in the setting of decreased *MAGO*H dosage may compromise cell viability by perturbing RNA splicing and RNA surveillance. To evaluate the global transcriptomic consequences of *MAGOHB* inhibition, we performed RNA sequencing on hemizygous *MAGO*H-deleted ChagoK1 cells in the presence or absence

of *MAGOHB* knockdown, with or without ectopic re-expression of *MAGO*H. We observed an increased expression of NMD biotype transcripts on *MAGOHB* knockdown in ChagoK1 cells (Fig. 2a, left). In contrast, *MAGOHB* knockdown in *MAGO*H-reconstituted ChagoK1 cells was well tolerated without a notable shift in NMD biotype transcript distribution (Fig. 2a, right). We next sought to determine whether the upregulation of NMD isoforms on *MAGOHB* knockdown in ChagoK1 cells was occurring at the expense of other transcript biotypes. Among genes that had significantly upregulated NMD isoform(s) on *MAGOHB* knockdown, we observed a significant proportional decrease in coding isoform expression in ChagoK1 cells but not *MAGO*H-reconstituted ChagoK1 cells (Fig. 2b, compare left and right). To investigate whether particular splice event classes were driving this redistribution of isoform types, we quantified the proportion of differentially spliced events of each class that were more common in either the absence (Fig. 2c, red) or presence (Fig. 2c, blue) of *MAGOHB* knockdown in either ChagoK1 cells or *MAGO*H-reconstituted ChagoK1 cells. As compared with *MAGOHB* knockdown in *MAGO*H-reconstituted ChagoK1 cells, *MAGOHB* knockdown in ChagoK1 cells resulted in reduced cassette exon inclusion and increased intron retention (Fig. 2c). Therefore, many global transcriptomic effects of *MAGO*H/B insufficiency appear attributable to alterations in these two splice event types, indicative of a defect in exon definition/recognition.


We identified 22 instances in which there was both a significant absolute upregulation of an NMD isoform (beta >1 in differential expression analysis using Kallisto<sup>19</sup>) and corresponding downregulation of at least one protein coding isoform (beta <−1) (Supplementary Table 7). These genes were significantly enriched for pathways involved in mRNA splicing and mRNA processing (Supplementary Table 8; Fig. 2d). Notably, among the seven splicing-related genes driving this enrichment were four genes (*SRSF2*, *SRSF7*, *HNRNPDL*, *HNRNPH1*) reported to auto-regulate their expression via alternative splicing–NMD (AS–NMD) loops<sup>20,21</sup>. Such AS–NMD loops, many of which are in splicing-related genes, involve ultraconserved, regulated alternative splicing events that induce NMD substrates, thus maintaining homeostatic control of gene expression<sup>20,21</sup>. We observed perturbations in isoform distributions of *HNRNPDL* and other splicing-related genes on *MAGOHB* knockdown in ChagoK1 cells, but not in *MAGO*H-reconstituted ChagoK1 cells (Fig. 2e; Supplementary Figs. 9 and 10; Supplementary Note). Altered RNA isoform abundance accompanied by changes in the levels of functional protein, either via disruption of AS–NMD loops or through other mechanisms, could have deleterious direct and indirect consequences on cellular splicing.

Given these transcriptomic consequences of *MAGO*H/*MAGOHB* insufficiency, we next sought to determine whether *MAGO*H loss unveils a broader dependency on splicing/NMD-related complexes. We performed immunoprecipitation and mass spectrometry to identify *MAGO*H- and *MAGOHB*-associated binding partners and found that these interactors, which include many splicing-related genes, were enriched for gene dependencies correlated with both *MAGO*H and *MAGOHB* dependencies. However, these dependencies were weaker than the reciprocal *MAGO*H/B paralog dependencies driven by redundant essentiality (Supplementary Fig. 11; Supplementary Tables 9–11; Supplementary Note).

*MAGO*H and *MAGOHB* share near-identity at the protein level and functional and crystallographic studies do not necessarily show domains easily amenable to targeting by small molecules<sup>22</sup>. To identify other more tractable targets that might indirectly affect *MAGO*H/*MAGOHB* function, we interrogated the genome-scale shRNA screening data for gene dependencies highly correlated with either *MAGO*H or *MAGOHB* dependency. *IPO13* emerged as the top, outlier-correlated gene dependency to both *MAGO*H and *MAGOHB* (Fig. 3a; Supplementary Table 12). *IPO13* is a bidirectional karyopherin responsible for nuclear import of the




**Fig. 1 | Hemizygous *MAGOHB* deletion confers *MAGOHB* dependency.** **a**, Analysis of paralog dependencies in genome-scale screening of cancer cell lines (shRNA, 501 lines; CRISPR-Cas9, 341 lines). **b**,  $q$ -value/ $q$ -value plot showing significance of pairwise correlation between a gene's dependency score and inactivation of its paralog.  $q$ -value 1, significance for dependency on the paralog labeled first with inactivation of the paralog labeled second.  $q$ -value 2, significance for dependency on the paralog labeled second with inactivation of the paralog labeled first. 'Symmetric' paralogs are in the upper right quadrant ( $q_1 < 0.05$  and  $q_2 < 0.05$ ). Plots show  $n = 1,970$  paralog pairs for shRNA data and  $n = 1,593$  pairs for CRISPR data. One-sided  $P$  value from two-class comparison was calculated via moderated  $t$ -statistic and adjusted for multiple comparisons using the Benjamini-Hochberg FDR. **c**, PARIS analysis to identify gene dependencies correlated with hemizygous *MAGOHB* loss. Mutual information metric (RNMI) is plotted against FDR for gene dependencies positively correlated with *MAGOHB* deletion. **d**, Cell viability in cell lines with (left) and without (right) hemizygous *MAGOHB* loss upon *MAGOHB* suppression using a doxycycline-inducible shRNA against *MAGOHB*. Error bars show mean  $\pm$  s.d.,  $n = 3$  replicates from a representative experiment repeated at least twice in each cell line;  $P$  value by two-tailed, two-sample  $t$ -test. Dox, doxycycline; NS, not significant. **e**, Colony formation in cell lines with (H1437, H460) or without (H1373) hemizygous *MAGOHB* loss upon *MAGOHB* suppression using a doxycycline-inducible shRNA against *MAGOHB*. Photographs show representative wells from an experiment conducted in triplicate (quantification in Supplementary Fig. 4); experiment was repeated at least twice in each cell line. **f**, Cell viability measured on *MAGOHB* knockdown in ChagoK1 cells with or without reconstitution of *MAGOHB*-V5. Error bars show mean  $\pm$  s.d.,  $n = 5$  replicates from a representative experiment repeated at least twice;  $P$  value by two-tailed, two-sample  $t$ -test. **g**, Frequency of hemizygous *MAGOHB* deletion across TCGA cohorts. Total frequency of *MAGOHB* loss is indicated by a light blue bar; frequency of *MAGOHB* loss occurring as a result of chromosome 1p deletion is indicated by a dark blue bar. Top panel shows total number of arm-level copy number events in each tumor type.



**Fig. 2 | RNA splicing is globally altered upon MAGOHB suppression in cells with MAGOH loss, leading to the upregulation of NMD substrates.**

**a**, Differentially expressed transcripts in ChagoK1 cells (left) and in MAGOH-V5 reconstituted ChagoK1 cells (right) on MAGOHB knockdown (KD). Transcripts annotated as NMD substrates shown in red. **Significance determined by a Wald test and adjusted for multiple comparisons using the Benjamini-Hochberg FDR.  $n = 3$  replicates were used in all conditions.** **b**, Density distribution of proportional expression levels among coding isoforms corresponding to genes whose NMD isoforms are upregulated upon MAGOHB knockdown in ChagoK1 cells (left) or MAGOH-V5 reconstituted ChagoK1 cells (right). X axis shows expression level of coding isoform(s) proportional to all expressed transcripts for a given gene. Y axis shows density. **c**, Global changes in patterns of splice site usage upon MAGOHB knockdown in ChagoK1 cells (left) or MAGOH-V5 reconstituted ChagoK1 cells (right). Splice event classes are shown in the schematic at top; solid lines denote 'inclusion' event and dotted lines denote the 'alternative' event for each class. Bar graphs denote the proportion of significant differentially spliced events that show greater inclusion in either the absence (red) or presence (blue) of MAGOHB knockdown in either ChagoK1 cells (left) or MAGOH-V5 reconstituted ChagoK1 cells (right). **d**, Significantly enriched gene ontology (GO) classes for genes ( $n = 17$ ) that show upregulation of NMD isoform(s) and concomitant downregulation of coding isoform(s). Significance was determined by a binomial test and adjusted for multiple comparisons using the Bonferroni correction. **e**, Left panel shows Sashimi plots around an activated exon within the 3'UTR of the *HNRNPDL* gene (inclusion of which creates an NMD-substrate transcript) in either the absence or presence of MAGOHB knockdown in either ChagoK1 cells or MAGOH-V5 reconstituted ChagoK1 cells. Numbers reflect junction spanning reads averaged over three replicates for each condition. Right panel, top left: transcript abundances for various isoforms of the *HNRNPDL* gene (labeled by the last six digits of the ENSEMBL ID) in either the absence (gray) or presence (red) of MAGOHB knockdown in either ChagoK1 cells or MAGOH-V5 reconstituted ChagoK1 cells. Right panel, top right: isoform abundances grouped by predicted coding protein length in each condition. aa, amino acid; tpm, transcripts per million. Right panel, bottom: western blot showing increased HNRNPDL protein levels on MAGOHB knockdown in ChagoK1 cells but not MAGOH-V5 reconstituted ChagoK1 cells. Representative of a similar experiment repeated three times.





**Fig. 3 | *IPO13* dependency is correlated with *MAGOHB* and *MAGOHB* dependencies and is rescued by *MAGOHB* reconstitution.** **a**, Plot of gene dependencies ( $n = 6,300$ ) correlated with *MAGOHB* dependency versus those correlated with *MAGOHB* dependency. Axes reflect Z-scored Pearson correlation of each dependency with either *MAGOHB* dependency (x axis) or *MAGOHB* dependency (y axis). *MAGOHB* and *MAGOHB* self-correlations are not shown. **b**, Heatmap of *IPO13* dependency scores across 243 screened cell lines. Black bars denote cell lines that share dependency on *IPO13* and either *MAGOHB*, *MAGOHB*, or both (1); cell lines that carry a hemizygous deletion in *IPO13* (2); *MAGOHB* (3); and *MAGOHB* (4). **c**, Cell viability measured on shRNA-mediated *IPO13* knockdown in cell lines without (HCC1359, left) and with (H1437, right) *MAGOHB* loss. Error bars show mean  $\pm$  s.d.,  $n = 4$  replicates per cell line; *P* value by two-tailed, two-sample *t*-test. **d**, Colony formation in *MAGOHB*-deleted H460 cells on *IPO13* knockdown in either the absence (top) or presence (bottom) of *MAGOHB*-V5 reconstitution. Photographs show representative wells from an experiment conducted in triplicate (quantification in Supplementary Fig. 12); experiment was repeated three times. **e**, Fold change in expression of the NMD substrates SC1.6 and SC1.7 of the *SRSF2* gene in H460 cells on *IPO13* knockdown (*IPO13*-sh2) in either the presence (red) or absence (blue) of *MAGOHB*-V5 reconstitution. Data normalized to expression in the shGFP condition. Error bars show mean  $\pm$  s.d.,  $n = 3$  technical replicates per condition.


*MAGOHB*-Y14 heterodimer, a function critical for recycling of the EJC; it is also located on chromosome 1p in proximity to *MAGOHB*, and the two genes are frequently codeleted<sup>17</sup> (Fig. 3b; Supplementary Table 13).

We observed a selective *IPO13* dependency in *MAGOHB*-deleted cell lines compared to non-deleted cell lines (Fig. 3c) and found that dependency on *IPO13* in *MAGOHB*-deleted H460 and H1437 cells was partially attenuated by *MAGOHB* re-expression (Fig. 3d; Supplementary Fig. 12; Supplementary Note). Knockdown of *IPO13* in *MAGOHB*-deleted cells led to cytoplasmic accumulation of *MAGOHB*/*MAGOHB* and subsequent upregulation of the NMD-substrates SC1.6 and SC1.7, an effect that was rescued by *MAGOHB* re-expression (Fig. 3e; Supplementary Fig. 13). This suggests that *IPO13* dependency in *MAGOHB*- and *MAGOHB*-deleted cells is mediated in part by defective shuttling of *MAGOHB*/B, resulting in mis-splicing and impaired RNA surveillance. Haploinsufficiency of *IPO13*, as occurs when *MAGOHB* and *IPO13* are codeleted, may also contribute to *IPO13* dependency in some contexts.

Finally, we sought to validate *MAGOHB* as a target in vivo. We formed xenografts from H1437 cells (which carry a hemizygous deletion in *MAGOHB*) transduced with a lentiviral vector encoding a doxycycline-inducible shRNA against *MAGOHB*. Xenograft growth was significantly impaired on *MAGOHB* knockdown. (Fig. 4a,b). To next assess this dependency using a more therapeutically tractable system, we used tumor-penetrating nanocomplexes (TPNCs) capable of targeted delivery of short interfering RNAs (siRNAs) to the cytosol of tumor cells<sup>23</sup>. The TPNCs were decorated with the tumor-homing peptide iRGD, which allows for targeted delivery of siRNAs to tumor cells expressing surface NRP1/ $\alpha$ v $\beta$ 3; both receptors

are expressed on H1437 cells (Fig. 4c). H1437 xenograft growth was significantly impaired on intratumoral injection of si-*MAGOHB*- and si-*IPO13*-containing TPNCs, but not TPNCs containing control siRNA against GFP (Fig. 4d,e; Supplementary Fig. 14). This finding was confirmed using a second TPNC system using a distinct tumor-homing peptide, Lyp-1 (Supplementary Fig. 14). Additionally, tumors treated with si-*MAGOHB*-containing TPNCs displayed higher levels of cleaved caspase-3, indicating that targeting *MAGOHB* in a *MAGOHB*-hemizygous context triggers apoptotic cell death (Supplementary Fig. 14). Thus, *MAGOHB* and *IPO13* represent potential in vivo targets in a *MAGOHB*-deleted context, and this paralog vulnerability may be exploited by antisense or RNAi-based approaches.

Hemizygous chromosome arm loss is one of the commonest features of cancer genomes<sup>24,25</sup> and rational therapeutic targeting of this class of somatic events would therefore be attractive. Prior studies have identified several candidate targets unmasked by genomic loss<sup>4,5,26,27</sup>. Here, we integrate genomic characterization and genome-scale functional screening of cancer cell lines to systematically extend such studies. We identify a set of robust paralog dependencies that may provide the foundation for future target validation efforts and show that hemizygous loss of the *MAGOHB* gene on chromosome 1p confers novel vulnerabilities on *MAGOHB* and *IPO13*, perhaps due to decreased nuclear reserve of *MAGOHB*/*MAGOHB* (Supplementary Fig. 15). Insufficient *MAGOHB*/*MAGOHB* dosage perturbs splicing and RNA surveillance and adds to growing evidence implicating splicing as a cancer dependency<sup>27–29</sup>. Therapeutic approaches to targeting *MAGOHB*-deleted cells may involve either direct *MAGOHB*



**Fig. 4 | *MAGOHB* and *IPO13* are in vivo dependencies in *MAGOHB*-deleted xenografts. **a,b**, Schematic (**a**) and growth curves (**b**) of H1437 xenografts in nude mice on *MAGOHB* suppression. H1437 cells were transduced with lentivirus expressing a doxycycline-inducible shRNA against *MAGOHB* and injected into the flanks of nude mice. Once palpable tumors had formed (7 days), mice were randomized to either normal chow or chow supplemented with doxycycline. Tumor volume over time is plotted in each arm. Lines show mean  $\pm$  s.e.m. for  $n = 6$  tumors per arm.  $P$  values listed for significant ( $<0.05$ ) time points by two-tailed, two-sample  $t$ -test;  $P$  also  $<0.0001$  by two-way analysis of variance (ANOVA) between +Dox and –Dox curves. **c**, Surface expression for NRP-1 and  $\alpha$ V $\beta$ 3 (co-receptors for IRGD-containing nanocomplexes) in H1437 cells, as assessed by flow cytometry. Repeated twice with similar results. **d,e**, Schematic (**d**) and growth curves (**e**) of H1437 xenografts in nude mice on *MAGOHB* or *IPO13* suppression using an siRNA-carrying TPNC. Following palpable tumor formation, mice received intratumoral injections of TPNC containing siRNA against GFP (control), *MAGOHB*, or *IPO13*. Lines show mean  $\pm$  s.e.m. for  $n = 10$  tumors per arm;  $P$  value by two-way ANOVA.**

transcript suppression (such as through antisense/RNAi approaches), targeted *MAGOHB* protein degradation, or indirect suppression of *MAGOHB* activity via inhibition of *IPO13*. Antisense/RNAi-based approaches may be well suited to the exploitation of paralog dependencies, as they may allow for selective targeting of paralogs that show greater variability on the nucleotide level than on the protein level. Targeted protein degradation approaches have also recently proven to be a promising means to target conventionally ‘undruggable’ genes<sup>30–33</sup>, including RNA splicing factors<sup>34</sup>. In the case of *IPO13* dependency, small-molecule inhibitors of other importin family members have been described, raising the possibility that *IPO13* can be selectively targeted using a similar strategy<sup>35–37</sup>. As hemizygous loss of chromosome 1p is extremely common across multiple tumor types, these or other approaches to targeting this pathway may have future biomarker-driven therapeutic applications. More broadly, our work can be generalized to cancers with other chromosome arm deletions and underscores the power of intersecting comprehensive molecular characterization and functional genomic studies of cancer cell lines.

**URLs.** Broad RNAi Consortium, <http://www.broadinstitute.org/rnai/public>; LentiCRISPRv2 Cloning Protocol, <http://genome-engineering.org/gecko/wp-content/uploads/2013/12/lentiCRISPRv2-and-lentiGuide-oligo-cloning-protocol.pdf>; Lentiviral Production Protocol, <http://portals.broadinstitute.org/gpp/public/resources/protocols>; Bash script for expectation maximization algorithm, <http://www.lagelab.org/resources>; HUGO Gene Nomenclature Committee, <http://www.genenames.org/cgi-bin/genefamilies>;

rMATS2Sashimiplot, <https://github.com/Xinglab/rmats2sashimiplot>; ENSEMBL Biomart, <http://www.ensembl.org/biomart> DepMap Portal, <http://depmap.org>; MassIVE, <http://massive.ucsd.edu>; NCBI GEO, <https://www.ncbi.nlm.nih.gov/geo/>; GO website, [www.geneontology.org](http://www.geneontology.org).

## Methods

Methods, including statements of data availability and any associated accession codes and references, are available at <https://doi.org/10.1038/s41588-018-0155-3>.

Received: 10 October 2017; Accepted: 10 May 2018;  
Published online: 28 June 2018

## References

- Diss, G. et al. Gene duplication can impart fragility, not robustness, in the yeast protein interaction network. *Science* **355**, 630–634 (2017).
- Muller, F. L., Aquilanti, E. A. & DePinho, R. A. Collateral lethality: a new therapeutic strategy in oncology. *Trends Cancer* **1**, 161–173 (2015).
- Frei, E. Gene deletion: a new target for cancer chemotherapy. *Lancet* **342**, 662–664 (1993).
- McDonald, E. R. 3rd et al. Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. *Cell* **170**, 577–592.e10 (2017).
- Tsherniak, A. et al. Defining a cancer dependency map. *Cell* **170**, 564–576.e16 (2017).
- Boehm, V. & Gehring, N. H. Exon junction complexes: supervising the gene expression assembly line. *Trends Genet.* **32**, 724–735 (2016).
- Chang, Y.-F., Imam, J. S. & Wilkinson, M. F. The nonsense-mediated decay RNA surveillance pathway. *Annu. Rev. Biochem.* **76**, 51–74 (2007).

8. Singh, K. K., Wachsmuth, L., Kulozik, A. E. & Gehring, N. H. Two mammalian MAGOH genes contribute to exon junction complex composition and nonsense-mediated decay. *RNA Biol.* **10**, 1291–1298 (2013).
9. Mingot, J.-M., Kostka, S., Kraft, R., Hartmann, E. & Görlich, D. Importin 13: a novel mediator of nuclear import and export. *EMBO J.* **20**, 3685–3694 (2001).
10. Helming, K. C. et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. *Nat. Med.* **20**, 251–254 (2014).
11. Hoffman, G. R. et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. *Proc. Natl Acad. Sci. USA* **111**, 3128–3133 (2014).
12. D'Antonio, M. et al. Recessive cancer genes engage in negative genetic interactions with their functional paralogs. *Cell Rep.* **5**, 1519–1526 (2013).
13. Dey, P. et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. *Nature* **542**, 119–123 (2017).
14. Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. *Sci. Data* **1**, 140035 (2014).
15. Meyers, R. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. *Nat. Genet.* **49**, 1779–1784 (2017).
16. Veitia, R. A. Gene duplicates: agents of robustness or fragility? *Trends Genet.* **33**, 377–379 (2017).
17. Bono, F. & Gehring, N. H. Assembly, disassembly and recycling. *RNA Biol.* **8**, 24–29 (2011).
18. Caron, H. et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. *N. Engl. J. Med.* **334**, 225–230 (1996).
19. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).
20. Ni, J. Z. et al. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. *Genes Dev.* **21**, 708–718 (2007).
21. Lareau, L. F., Inada, M., Green, R. E., Wengrod, J. C. & Brenner, S. E. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. *Nature* **446**, 926–929 (2007).
22. Lau, C.-K., Diem, M. D., Dreyfuss, G. & Van Duyne, G. D. Structure of the Y14-Magoh core of the exon junction complex. *Curr. Biol.* **13**, 933–941 (2003).
23. Ren, Y. et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. *Sci. Transl. Med.* **4**, 147ra112 (2012).
24. Beroukhi, R. et al. The landscape of somatic copy-number alteration across human cancers. *Nature* **463**, 899–905 (2010).
25. Baudis, M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. *BMC Cancer* **7**, 226 (2007).
26. Nijhawan, D. et al. Cancer vulnerabilities unveiled by genomic loss. *Cell* **150**, 842–854 (2012).
27. Paoletti, B. R. et al. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. *eLife* **6**, e23268 (2017).
28. Lee, S. C.-W. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. *Nat. Med.* **22**, 672–678 (2016).
29. Obeng, E. A. et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. *Cancer Cell* **30**, 404–417 (2016).
30. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science* **343**, 305–309 (2014).
31. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science* **343**, 301–305 (2014).
32. Hwang, S.-Y. et al. Direct targeting of  $\beta$ -catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/ $\beta$ -catenin signaling. *Cell Rep.* **16**, 28–36 (2016).
33. Kerres, N. et al. Chemically induced degradation of the oncogenic transcription factor BCL6. *Cell Rep.* **20**, 2860–2875 (2017).
34. Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. *Science* **356**, eaal3755 (2017).
35. Soderholm, J. F. et al. Importazole, a small molecule inhibitor of the transport receptor importin- $\beta$ . *ACS Chem. Biol.* **6**, 700–708 (2011).
36. Hintersteiner, M. et al. Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries. *ACS Chem. Biol.* **5**, 967–979 (2010).
37. Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D. & Jans, D. A. Ivermectin is a specific inhibitor of importin  $\alpha/\beta$ -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem. J.* **443**, 851–856 (2012).

## Acknowledgements

S.R.V. was supported by a Young Investigator Award from the American Society of Clinical Oncology. This work was supported by a National Cancer Institute grant 1R35CA197568 and an American Cancer Society Research Professorship to M.M. P.T. was supported by NIH grants U01CA217885 and R01HG009285. W.C.H. was supported by U01CA176058. C.G.B. and S.N.B. were supported by a Koch Institute Support Grant (P30-CA14051) from the National Cancer Institute (Swanson Biotechnology Center) and a Core Center Grant (P30-ES002109) from the National Institute of Environmental Health Sciences, and the Ludwig Center for Molecular Oncology. C.G.B. was supported by the National Science Foundation Graduate Research Fellowship Program. S.N.B. is a Howard Hughes Medical Institute Investigator. P.S.C. was supported by an NIH Pathway to Independence Award (K99 CA208028). E.M. would like to thank H. Horn for help with the expectation maximization algorithm. The authors thank the Koch Institute Swanson Biotechnology Center for technical support, specifically K. Cormier in the Hope Babette Tang Histology Facility.

## Author contributions

S.R.V. and M.M. conceived of the research and wrote the manuscript. S.R.V. and M.F.N. performed experiments. C.G.B. performed in vivo xenograft experiments. M.J.W., S.R.V., and P.S.C. performed data analysis on RNA sequencing data. J.M.K.-B. and S.R.V. performed data analysis on shRNA and CRISPR screening data. A.C.B., A.M.T., and J.S. performed copy number analysis on TCGA and cell line data. C.A.S. assisted in generation of shRNA reagents. P.T., A.D.C., and C.S.P. performed or oversaw data analysis. B.T., K.L., S.A.C., E.M., and M.S. performed mass spectrometry or were involved in downstream data analysis. S.N.B. oversaw in vivo xenograft experiments. F.V., A.T., and W.C.H. directed shRNA and CRISPR screening efforts. M.M. directed the overall project.

## Competing interests

A.C.B., A.D.C., C.A.S., and M.M. receive research support from Bayer Pharmaceuticals. M.M. is a scientific advisory board member of, consultant for, and holds equity in OrigiMed. The content of this manuscript is the subject of a pending patent application (S.V., M.M.).

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41588-018-0155-3>.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Correspondence and requests for materials** should be addressed to M.M.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



## Methods

**Cell culture.** Cell line stocks used for validation experiments were obtained either from the Cancer Cell Line Encyclopedia (CCLE) repository at the Broad Institute or from M.M.'s laboratory, with original sources being either the American Type Culture Collection, the European Collection of Authenticated Cell Cultures, the Health Science Research Resources Bank, the Korean Cell Line Bank, or academic laboratories. Cell line identity was verified by either short tandem repeat profiling or Affymetrix SNP profiling. Cells were cultured in media specified by the source repository, supplemented with 100 international units  $\text{ml}^{-1}$  penicillin, 100  $\mu\text{g ml}^{-1}$  streptomycin, 2 mM L-glutamine, and 100  $\mu\text{g ml}^{-1}$  Normocin (Invivogen). Mycoplasma testing was performed in source repository before creation of frozen stocks and repeated periodically if lines were persistently maintained in culture.

**Lentiviral constructs and transduction of cell lines.** For overexpression experiments, ORFs were expressed from within the pLX304-Blast-V5 vector<sup>38</sup> (Addgene no. 25890, Blasticidin resistance) using pLX304-eGFP as an overexpression negative control. Ectopic expression of untagged MAGOH was performed using either pLX304 (with stop codon introduced before V5 tag) or Gateway-compatible, hygromycin-resistant, doxycycline-inducible overexpression vector with complementary DNA expression driven from Tet-regulated cytomegalovirus promoter, created by modification of prior similar vectors<sup>39,40</sup>. MAGOH-reconstitution experiments were performed with V5-tagged MAGOH with the exception of those shown in Supplementary Fig. 4f, which were performed using an untagged construct. For shRNA experiments, constitutive shRNAs were expressed from the pLKO.1 vector<sup>41</sup> (Addgene no. 10878, puromycin resistance) using an shRNA targeting GFP (shGFP) as a negative control. shRNA constructs were obtained from the RNAi Consortium shRNA collection (see URLs). Inducible shRNAs were cloned into a Gateway-compatible doxycycline-inducible lentiviral shRNA expression system (G418 resistance), as described<sup>39</sup>. Single guide RNAs (sgRNAs) were cloned into lentiCRISPRv2 (Addgene no. 52961) as described (see URLs). shRNA and sgRNA target sequences are listed in Supplementary Table 14.

Lentivirus was produced in HEK293T cells as per the 'low throughput viral production' protocol on the RNAi Consortium Portal (see URLs). Cells were transduced with lentivirus by spin-infection (2250 rpm for 30 minutes) in the presence of 8  $\mu\text{g ml}^{-1}$  polybrene, followed by antibiotic selection beginning 24 hours thereafter. Following completion of antibiotic selection, cells were seeded for downstream assays as described.

Gene knockdown or knockout was confirmed by quantitative PCR (qPCR) with reverse transcription for *MAGOH/B* as the paralogs cannot be distinguished on western blotting. Gene overexpression was confirmed by western blotting.

**Generation of *MAGOH*-knockout cell lines.** For generation of *MAGOH*-knockout cell lines, Heya8 cells were transiently transfected with either a non-targeting guide (sgGFP) or *MAGOH* sgRNA expressed from within plentiCRISPRv2. Following 72 hours of selection with puromycin, the bulk resistant population was sorted at single-cell density into 96-well plates using a MoFlo Astrios Cell Sorter (Beckman Coulter). Clonal cell lines were expanded and assessed for *MAGOH* knockout by qPCR.

**Western blotting.** Whole-cell extracts for immunoblotting were prepared by incubating cells on ice in RIPA lysis buffer (Thermo Fisher Scientific) plus protease inhibitors (cOmplete, Mini, EDTA-free, Roche) for 20 minutes. Following centrifugation (>16,000g for 15 minutes), protein lysates were quantitated using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Lysates were separated by SDS-PAGE and transferred to nitrocellulose membranes using the iBlot2 system (Life Technologies). Two-color immunoblotting was performed using the LI-COR platform (LI-COR Biosciences) with IRDye 800CW and IRDye680RD secondary antibodies (mouse, IRDye 680LT Donkey anti-Mouse IgG (925-68022) used at 1:10,000; rabbit, IRDye 800CW Goat anti-Rabbit IgG (926-32211) used at 1:10,000). Imaging was performed on an Odyssey CLx Infrared Imaging System. Loading control and experimental protein were probed on the same membrane in all cases. For clarity, loading control is cropped and shown below experimental condition in all panels regardless of relative molecular weights of the two proteins.

Primary antibodies and dilutions used were as follows. HNRNPDL: Thermo Fisher Scientific (PA5-35896), 1:2,000. Vinculin: Sigma-Aldrich (V9264), 1:4,000. *MAGOH*: Santa Cruz Biotechnology (sc-271365), 1:250 or Abcam (ab38768) (1:500). Actin: Cell Signaling Technology (D6A8, monoclonal antibody no. 8457), 1:1,000 or Cell Signaling Technology (8H10D10, monoclonal antibody no. 3700), 1:2,000. PSPC1: Santa Cruz Biotechnology (sc-374181), 1:100. HNRNP1: Bethyl Laboratories (A300-511A), 1:1,000.

**qPCR.** RNA isolation was performed using the RNeasy Mini Kit (Qiagen). cDNA preparation was performed using Superscript III cDNA synthesis kit (Thermo Fisher Scientific). PCR reactions were prepared using TaqMan Gene Expression Mastermix (Thermo Fisher Scientific) and PrimeTime qPCR probe-based assays (IDT) using *HPRT1* as an internal normalization control. TaqMan assay identity catalog numbers are as provided in Supplementary Table 14. Real-time qPCR was performed on a QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) and results were quantitated using the  $\Delta\Delta\text{Ct}$  method. For quantification of SC35

NMD substrates, qPCR was performed using a Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) and primer sequences for SC1.6 and SC1.7 as described<sup>4</sup> using  $\beta$ -actin as an internal normalization control.

**Cell viability and colony formation assays.** For cell viability assays, cells were seeded in 96-well plates in 100  $\mu\text{l}$  medium after lentiviral transduction and completion of antibiotic selection. For inducible hairpin experiments, equal numbers of cells were seeded for both '-Dox' and '+Dox' conditions and medium was supplemented with 100  $\text{ng ml}^{-1}$  doxycycline in the '+Dox' condition. Cells were seeded in 96-well plate format (range 1,000–8,000 per well, depending on the cell line). At 7–10 days after cell seeding, cell viability was assessed using the Cell Titer-Glo luminescent cell viability assay (Promega) using either an EnVision Multilabel Reader (PerkinElmer) or a Spectramax M5 plate reader (Molecular Devices).

For colony formation assays, cells were seeded in 12-well plates at a density of 2,000–8,000 cells per well after lentiviral transduction and completion of antibiotic selection. Cells were cultured for 10–20 days. Colonies were fixed in 4% formaldehyde and stained with 0.5% crystal violet. Cells were photographed using a Leica microscope. Colonies were then destained using 10% acetic acid and crystal violet staining was quantified by measuring absorbance at 595 nm using a Spectramax M5 instrument (Molecular Devices).

**Immunofluorescence.** For immunofluorescence assays, 200,000 cells were plated on SecureSlip silicone supported coverglasses (Sigma Aldrich) in 6-well plates that had been precoated for 60 minutes with 0.01  $\text{mg ml}^{-1}$  human fibronectin (Calbiochem) in PBS. The following day, cells were fixed in 4% paraformaldehyde diluted in PBS for 15 minutes at room temperature. Cells were permeabilized with 0.2% Triton X-100 in PBS for 10 minutes. Blocking was performed in 2.5% normal goat serum blocking solution (Vector Laboratories). Cells were incubated in primary *MAGOH/MAGOH*B antibody (Abcam, ab38768, rabbit, 1:200) for 1 hour at room temperature. A Cy-3 conjugated anti-rabbit secondary (Abcam, ab97075, 1:200) and DAPI (Life Technologies, 1:1,000) were then used for 1 hour at room temperature. Cells were mounted and imaged on an Axio Observer fluorescent microscope (Zeiss) using AxioVision software (Zeiss). Nuclear/cytoplasmic ratio was quantified by Image J. Nuclear outlines were determined based on DAPI signal. Cytoplasmic signal was defined as signal in the whole cell minus signal within the nuclear area.

**Mouse experiments.** Studies involving mice were approved by the MIT Committee on Animal Care. Mouse strain used was NCR-nude (Charles River Laboratories), female, 4–5 weeks of age. For inducible shRNA xenograft experiments, NCR-nude mice were subcutaneously injected into bilateral flanks with  $3.5 \times 10^6$  H1437 cells transduced with lentivirus expressing a doxycycline-inducible shRNA against *MAGOH*B (*MAGOH*B-sh2). Cells were resuspended in 100  $\mu\text{l}$  30% matrigel in PBS. At 7 days post injection, after tumor implantation, mice were randomized to match tumor size between two groups, and one group was started on a diet containing 200 mg doxycycline per kg (Bio-Serv). Tumor volumes were measured twice weekly using a digital caliper.

For TPNC experiments, xenografts were produced as above using  $2.5 \times 10^6$  cells per tumor. TPNCs were prepared by complexing siRNA with tandem peptide at a 1:20 (LyP1) or 1:15 (iRGD) molar ratio (siRNA/peptide) in water. For intratumoral injections, 0.2 nmol siRNA was injected every 1–2 days in 20  $\mu\text{l}$  TPNC solution. Myr-TP-LyP1 (myr-GWTLNSAGYLLGKINLKALAALAKKILGGGG-K(5TAMRA)-CGNKRTRGC (C-C bridge)) and Palm-TP-iRGD (palm-GWTLNSAGYLLGKINLKALAALAKKILGGGG-CRGDKGPDC (C-C bridge)) were synthesized by CPC Scientific. siRNAs were purchased from GE Dharmacon. *MAGOH*B siRNA target sequence was as in *MAGOH*B-sh2; *IPO13* siRNA target sequence was as in *IPO13*-sh3 (see Supplementary Table 14 for sequences). Surface expression of p32 or NRP-1 was evaluated by flow cytometry using anti-p32 antibody at 1:1,000 dilution (AB2991, EMD Millipore), anti-alpha V beta 3-PE conjugated antibody at 1:100 dilution (FAB3050P, R&D Systems), anti-Neuropilin1 antibody at 1:1,000 dilution (AB9600, Millipore), or matched isotype control, and visualized with AlexaFluor 647-labeled secondary antibody (p32 and NRP-1) or conjugated PE (avb3).

Immunostaining was performed as previously described<sup>42</sup>. Briefly, six tumors from each condition (randomly selected) were extracted and fixed in 10% formalin overnight and stored at 4°C before being embedded in paraffin, sectioned, and stained. Tumor sections were stained with primary antibody to Cleaved Caspase-3 (Asp175) (5A1E) Rabbit monoclonal antibody no. 9664 (Cell Signaling Technology, 1:1,000) and HRP-conjugated anti-rabbit secondary antibody (RABBIT-ON-RODENT HRP-POLYMER from BioCare Medical, cat. no. RMR622) on a ThermoScientific IHC Autostainer 360 and visualized with DAB chromogen. For cleaved caspase-3 quantification, fraction of cross-sectional area staining positive for cleaved caspase-3 was quantified in the six randomly selected tumors from each group that were stained, using ImageJ.

**Immunoprecipitation and mass spectrometry.** *Immunoprecipitation.* For immunoprecipitation experiments, 293 T cells were either untransduced (control) or transduced with pLX304-Blast-V5 (Addgene no. 25890) expressing *MAGOH*-V5 or *MAGOH*B-V5. Following antibiotic selection to derive stably



transduced cell populations, immunoprecipitation was carried out using the Pierce Class Magnetic IP Kit (no. 88804) and anti-V5 magnetic beads (MBL no. M167-11) using a starting amount of 2 mg protein and 50  $\mu$ l beads. Lysis buffer was pH 7.4, 0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% NP40, and 5% glycerol. Immunoprecipitation was carried out overnight at 4°C. Samples were washed twice in sample buffer, followed by twice in PBS, before mass spectrometry. Efficient immunoprecipitation was confirmed by western blotting before proceeding with mass spectrometry.

**Protein digestion and labeling with tandem mass tag (TMT) isobaric mass tags.** The beads from immunoprecipitation were washed once with IP lysis buffer, then three times with PBS. The four different lysates of each replicate were resuspended in 90  $\mu$ l digestion buffer (2 M urea, 50 mM Tris HCl) and then 2  $\mu$ g sequencing grade trypsin was added, followed by 1 hour of shaking at 700 rpm. The supernatant was removed and placed in a fresh tube. The beads were then washed twice with 50  $\mu$ l digestion buffer and combined with the supernatant. The combined supernatants were reduced (2  $\mu$ l 500 mM dithiothreitol, 30 minutes, room temperature) and alkylated (4  $\mu$ l 500 mM iodoacetamide, 45 minutes, dark), and a longer overnight digestion was performed: 2  $\mu$ g (4  $\mu$ l) trypsin, shaken overnight. The samples were then quenched with 20  $\mu$ l 10% formic acid and desalted on 10 mg Oasis cartridges.

Desalted peptides were labeled with TMT6 reagents lot QD218427 (Thermo Fisher Scientific) according to the following: 126, NoBaitCntlRep1; 127, NoBaitCntlRep2; 128, MAGOHRep1; 129, MAGOHRep2; 130, MAGOHRep1; 131, MAGOHRep2. Peptides were dissolved in 25  $\mu$ l fresh 100 mM HEPES buffer. The labeling reagent was resuspended in 42  $\mu$ l acetonitrile and 10  $\mu$ l added to each sample as described below. After 1 hour incubation the reaction was stopped with 8  $\mu$ l 5 mM hydroxylamine.

**Protein identification with a nanoLC-MS system.** Reconstituted peptides were separated on an online nanoflow EASY-nLC 1000 UHPLC system (Thermo Fisher Scientific) and analyzed on a benchtop Orbitrap Q Exactive Plus mass spectrometer (Thermo Fisher Scientific). The peptide samples were injected onto a capillary column (Pico frit with 10  $\mu$ m tip opening/75  $\mu$ m diameter, New Objective, PF360-75-10-N-5) packed in-house with 20 cm C18 silica material (1.9  $\mu$ m ReproSil-Pur C18-AQ medium, Dr. Maisch GmbH) and heated to 50°C in column heater sleeves (Phoenix-ST) to reduce backpressure during UHPLC separation. Injected peptides were separated at a flow rate of 200 nl min<sup>-1</sup> with a linear 230 min gradient from 100% solvent A (3% acetonitrile, 0.1% formic acid) to 30% solvent B (90% acetonitrile, 0.1% formic acid), followed by a linear 9 min gradient from 30% solvent B to 60% solvent B and a 1 min ramp to 90% B. Each sample was run for 260 min, including sample loading and column equilibration times. The Q Exactive instrument was operated in the data-dependent mode acquiring higher-energy collisional dissociation (HCD) tandem mass spectrometry (MS/MS) scans ( $R=17,500$ ) after each MS1 scan ( $R=70,000$ ) on the 12 top most abundant ions using an MS1 ion target of  $3 \times 10^6$  ions and an MS2 target of  $5 \times 10^4$  ions. The maximum ion time utilized for the MS/MS scans was 120 ms; the HCD-normalized collision energy was set to 27; the dynamic exclusion time was set to 20 s; and the peptide match and isotope exclusion functions were enabled.

**Database search and data processing.** All mass spectra were processed using the Spectrum Mill software package v6.0 prerelease (Agilent Technologies), which includes modules developed by us for TMT6-based quantification. For peptide identification MS/MS spectra were searched against the human Uniprot database to which a set of common laboratory contaminant proteins was appended. Search parameters included ESI-QEXACTIVE-HCD scoring parameters, trypsin enzyme specificity with a maximum of two missed cleavages, 40% minimum matched peak intensity,  $\pm 20$  ppm precursor mass tolerance,  $\pm 20$  ppm product mass tolerance, and carbamidomethylation of cysteines and TMT6 labeling of lysines and peptide N termini as fixed modifications. Allowed variable modifications were oxidation of methionine, N-terminal acetylation, pyroglutamic acid (N-termQ), deamidated (N), pyro carbamidomethyl Cys (N-termC), with a precursor MH<sup>+</sup> shift range of  $-18$ – $64$  Da. Identities interpreted for individual spectra were automatically designated as valid by optimizing score and delta rank1-rank2 score thresholds separately for each precursor charge state in each liquid chromatography-MS/MS while allowing a maximum target-decoy-based false-discovery rate (FDR) of 1.0% at the spectrum level.

**Analysis.** The expectation maximization algorithm<sup>43</sup> was applied to the results of the peptide report (the in-house written bash script is available on the Lage Lab Resources Site (see URLs) and the peptide report can be found in the supplementary material). The list of most likely observed proteins was generated for each channel of the mass spectrometry experiment based on Swiss-Prot and TrEMBL databases of protein sequences<sup>44</sup>. Next, ratios of intensities between channels were calculated and median normalized. Resulting data were analyzed and visualized using R. Statistical analyses were performed via moderated *t*-test from R package limma<sup>45</sup> to estimate *P* values for each protein and the FDR corrections were applied to account for multiple hypotheses testing. Plots were created using in-house written R scripts and gplot2<sup>46</sup>. RNA-binding and S ribosomal protein families were taken from the HUGO Gene Nomenclature

Committee (see URLs). Proteins previously reported to be EJC/NMD complex members<sup>7</sup> were annotated as such.

**Analysis of cancer cell lines. Copy number analysis.** Details regarding arm-level copy number calling are as described by Taylor and colleagues<sup>47</sup>. Briefly, to determine arm-level events (that is, 1p or 12p deletion status) in TCGA and CCLE samples, the ABSOLUTE algorithm<sup>48</sup> was used to determine the likeliest ploidy and absolute total copy number of each genomic segment. Segments were called as amplified, deleted, or copy neutral based on copy number with reference to integer-rounded ploidy. Arm- or chromosome-level amplification/deletion status was then determined from segment data as described by Taylor and colleagues<sup>47</sup>. CCLE cell lines were fit to clusters within their corresponding TCGA tumor type to generate cell line-specific, arm-specific calls<sup>49</sup>. For CCLE data, ABSOLUTE algorithm was run on the CCLE Affymetrix SNP6.0 array data as previously reported<sup>50</sup>. For analysis of arm level and focal copy number event in TCGA data sets, 1p deletion status was determined as described above. Hemizygous *MAGOH* deletion was defined as the loss of one or more copies of the *MAGOH* gene (for example, ploidy – *MAGOH* copy number  $\geq 1$ ) using rounded tumor ploidy and *MAGOH* copy number calculated from the ABSOLUTE algorithm.

**Genome-scale shRNA and CRISPR screening data analysis.** Genome-wide shRNA screening on 501 cell lines was performed as described<sup>1</sup>. The DEMETER method, which summarizes multiple shRNAs targeting a gene into a gene-level dependency score, was used to quantify gene dependency in 17,098 unique genes<sup>5</sup>. The differential dependency set of 6,305 genes, and the 6 $\sigma$  dependency set of 769 genes, as defined previously<sup>1</sup>, were used for all downstream analyses. These sets represent the genes with the most significant differential dependency across cell lines and were selected based on the following criteria: (1) for each gene, there is at least one cell line with a dependency score that is two (differential set) or six (6 $\sigma$  set) standard deviations from the mean of scores from all genes and all cell lines, and (2) expression of the gene in the most dependent cell line is above  $-2\log_2$  reads per kilobase million.

To identify synthetic lethal relationships linked to loss of a paralog, a query was performed for each of 17,670 genes using EnsemblCompara<sup>51</sup> via the R interface to BioMart<sup>52</sup> to obtain a list of paralogs and their pairwise sequence identity. Pearson correlations of RNA sequencing (RNA-seq) expression values between genes in each paralog pair indicate that co-expression is limited until DNA sequence identity exceeds 25% (Supplementary Fig. 1). To increase the likelihood that the gene pairs function redundantly, pairs with less than 25% sequence identity were removed. An additional 35 genes were removed for having duplicate DEMETER scores (caused by non-unique hairpins), resulting in 3,403 genes in the DEMETER dataset with at least one paralog. Differential dependency for each of these genes was tested by grouping cell lines based on loss of the gene's paralogs and performing a two-class comparison of the DEMETER scores using empirical Bayes moderated *t*-statistics implemented by the R package limma<sup>45</sup>. The binary classification of paralog loss used to group the cell lines was determined by a logic combination of the RNA-seq gene expression, protein abundance (RPPA), relative copy number, methylation fraction (RRBS), and mutation status (whole-exome sequencing, whole-genome sequencing, RNA-seq). The gene expression, RPPA, copy number, and RRBS datasets are z-scored per gene so loss of a gene is defined as having a 6 $\sigma$  decrease in gene expression or RPPA, or no gene expression at all (less than  $-3\log_2$  transcripts per million), 2 $\sigma$  decrease in copy number, 6 $\sigma$  increase in RRBS, or a deleterious mutation (predicted by frameshift indel or nonsense single-nucleotide variant). Genes are labeled 'symmetric' if loss of either gene in a pair is significantly associated with a selective dependency on its respective paralog gene with FDR  $< 0.05$ .

The synthetic lethal paralog analysis was repeated using the Achilles CRISPR dataset<sup>15</sup> consisting of 341 whole genome CRISPR/cas9 knockout screens corrected for copy number effects (one cell line, PK59, was removed from the prior set of 342 as it failed fingerprinting). Genes with variance in essentiality below 0.01 across the 341 cell lines were removed to reduce false positives, leaving 6,535 genes for paralog dependency analysis. The definition of gene loss as well as method for determining significance of differential dependency among each paralog pair is identical to the analysis using DEMETER data.

For analysis of gene dependencies correlated with *MAGOH* deletion (Fig. 1), the Probability Analysis by Ranked Information Score (PARIS) algorithm was run as a GenePattern module (see URLs). *MAGOH*-deletion status was determined by the ABSOLUTE algorithm<sup>48</sup> as described above. Cell lines for which *MAGOH* absolute copy number was less than the cell line's ploidy were considered deleted. Based on available ABSOLUTE calls, 191 lines were considered deleted and 807 lines were considered non-deleted. In total, both absolute copy number and filtered DEMETER gene-score data were available for 445 overlap cell lines.

For geneset enrichment analysis on gene dependencies correlated with *MAGOH* deletion, the PARIS algorithm was first run using continuous copy number data on CCLE cell lines generated using SNP arrays, as previously reported<sup>50</sup>, to generate a ranked list of gene dependencies correlated with *MAGOH* copy number. RNMI metric score for each gene was then used as input for preranked geneset enrichment analysis<sup>53</sup>, which was run as a GenePattern module using default parameters against the following genesets:

REACTOME\_NONSENSE\_MEDIATED\_DECAY\_ENHANCED\_BY\_THE\_EXON\_JUNCTION\_COMPLEX and GO\_NUCLEAR\_TRANSCRIBED\_MRNA\_CATABOLIC\_PROCESS\_NONSENSE\_MEDIATED\_DECAY

For analysis of correlated gene dependency profiles, Pearson correlations of DEMETER gene dependency scores were computed across cell lines ( $N=501$ ) for all pairs of genes that share overlap in cell lines ( $N=6,300$ ). Correlation coefficients were converted to standard scores across the full correlation matrix before evaluating the specific *MAGOH* and *MAGOHB* correlation profiles.

**RNA-seq analysis.** RNA-seq libraries were prepared using the Illumina strand-specific mRNA-seq Library Prep Kit (Illumina) followed by paired-end 75 bp sequencing on a NextSeq ( $>400$  M reads per run;  $>33$  M reads per sample). Transcript levels were quantified with kallisto<sup>19</sup> (version 0.43.0, options: `-rf-stranded, -b 30`) using the GRCh38 transcriptome (ENSEMBL cDNA, release 87)<sup>24</sup>. Differential expression analysis was performed with sleuth<sup>55</sup> (version 0.28.1). Differential expression was quantified based on the beta value, a bias estimator used by kallisto<sup>19</sup> analogous to fold-change. Significant upregulation cut-offs were  $b > 1$ ,  $q < 0.01$ ; downregulation  $b < -1$ . Gene Ontology<sup>56</sup> term enrichment analysis was carried out using PANTHER<sup>57</sup>; Overrepresentation Test (release 20160715) using the Gene Ontology database (release 2017-01-26), accessible via the Gene Ontology website (see URLs, last accessed 2017-01-31). Transcript biotypes were obtained from the ENSEMBL database (release 87)<sup>24</sup>. For analysis of differential alternative splicing events, reads were aligned with HiSat2 (v2.0.4, `-rna-strandness RF` option)<sup>58</sup> using the prebuilt index Ensembl GRCh38 (genome\_tran), and splicing events were quantified using rMATS v3.2.5<sup>59</sup>. For increased stringency, rMATS output was filtered based on read support (sum of inclusion/exclusion reads  $\geq 10$  in both samples), FDR ( $< 0.05$ ), and inclusion level difference ( $|\text{ILD}| > 0.1$ ). Sashimi plots were plotted using rMats2Sashimiplot (see URLs) in grouping mode.

For estimation of protein-level effects from RNA-seq data, peptide sequences for each transcript were obtained using ENSEMBL biomaRt (see URLs), accessed through the R package biomaRt (version 2.26.1)<sup>52,60</sup>. For each gene, expected peptide expression was then estimated by summing over transcript per million values for all transcripts that encode peptides of the same length.

**REVEALER analysis.** To identify associations between *MAGOH/B* dependency and copy number/expression features of EJC/splicing-related genes, *MAGOH* or *MAGOHB* dependency scores across screened cell lines<sup>5</sup> were correlated with copy number or expression features<sup>50</sup> in EJC/splicing-related genes using the previously described method based on estimating the information coefficient<sup>61</sup>. For radial plots, the top-scoring 50 features (for copy number) or top-scoring 16 features (for expression) were plotted. A list of EJC/splicing-related genes used for this analysis was compiled by combining EJC/NMD genes in MSigDB (Reactome geneset no. M1067) and splicing factors described as being implicated in oncogenesis<sup>62</sup>.

**Statistics.** No statistical methods were used to predetermine sample size. Investigators were not blinded to allocation for experiments. Statistical tests applied,  $P$  values, and sample size are as listed in figure captions. For in vitro experiments, number of biologically independent replicates is as listed in figure captions. When two-sample Student's  $t$ -tests were applied to assess significance of experimental data, unequal variance parameter was used and  $P$  values were calculated using Microsoft Excel (function `t.test`; heteroscedastic). Other statistical tests were performed using R (v. 3.4.1) or GraphPad Prism 7 software.

**Reporting Summary.** Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

**Data availability.** The original mass spectra may be downloaded from MassIVE (see URLs) using the identifier MSV000082292. RNA-seq data can be accessed at NCBI Gene Expression Omnibus (GSE113848) (see URLs). Code for analysis of IP-MS data is deposited in the Lage Lab website (see URLs). The authors declare that other data supporting the findings of this study are available within the paper

and its supplementary information files. Other source data are available from the corresponding author on reasonable request.

## References

- Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. *Nat. Methods* **8**, 659–661 (2011).
- Lippa, M. S. et al. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. *Apoptosis* **12**, 1465–1478 (2007).
- Brown, C. Y. et al. Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector. *Hum. Gene Ther.* **21**, 1005–1017 (2010).
- Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S. & Sabatini, D. M. Genome-scale loss-of-function screening with a lentiviral RNAi library. *Nat. Methods* **3**, 715–719 (2006).
- Kwon, E. J., Dudani, J. S. & Bhatia, S. N. Ultrasensitive tumour-penetrating nanosensors of protease activity. *Nat. Biomed. Eng.* **1**, 0054 (2017).
- McLachlan, G. J. & Krishnan, T. *The EM Algorithm and Extensions* 2nd edn (Wiley-Interscience, Hoboken, NJ, 2008).
- The UniProt Consortium. UniProt: the universal protein knowledgebase. *Nucleic Acids Res.* **45**, D158–D169 (2017).
- Ritchie, M. E. et al. *limma* powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
- Wickham, H. *ggplot2* <https://doi.org/10.1007/978-0-387-98141-3> (Springer, New York, 2009).
- Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. *Cancer Cell* **33**, 676–689 (2018).
- Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. *Nat. Biotechnol.* **30**, 413–421 (2012).
- Pedregosa, F. et al. Scikit-learn: machine learning in Python. *JMLR* **12**, 2825–2830 (2011).
- Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603–607 (2012).
- Vilella, A. J. et al. EnsemblCompara GeneTrees: complete, duplication-aware phylogenetic trees in vertebrates. *Genome Res.* **19**, 327–335 (2008).
- Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
- Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
- Aken, B. L. et al. Ensembl 2017. *Nucleic Acids Res.* **45**, D635–D642 (2017).
- Pimentel, H. J., Bray, N., Puente, S., Melsted, P. & Pachter, L. Differential analysis of RNA-seq incorporating quantification uncertainty. *Nat. Methods* **14**, 687–690 (2016).
- The Gene Ontology Consortium. Gene Ontology Consortium: going forward. *Nucleic Acids Res.* **43**, D1049–D1056 (2015).
- Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis with the PANTHER classification system. *Nat. Protoc.* **8**, 1551–1566 (2013).
- Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. *Nat. Methods* **12**, 357–360 (2015).
- Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-seq data. *Proc. Natl Acad. Sci. USA* **111**, E5593–E5601 (2014).
- Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2005).
- Kim, J. W. et al. Characterizing genomic alterations in cancer by complementary functional associations. *Nat. Biotechnol.* **34**, 539–546 (2016).
- Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. *Oncogene* **35**, 2413–2427 (2015).

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

n/a Confirmed

- ☐ ☒ The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- ☐ ☒ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- ☒ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☒ ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☐ ☒ Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated
- ☐ ☒ Clearly defined error bars  
*State explicitly what error bars represent (e.g. SD, SE, CI)*

Our web collection on [statistics for biologists](#) may be useful.

### Software and code

Policy information about [availability of computer code](#)

#### Data collection

1) RNA-Seq: Software used is publicly available and as described in Methods ("Analysis of Cancer Cell Lines" section; "RNA-Seq Analysis" sub-section)  
2) Data analysis of CCLE Cell Lines: Data was processed and analyzed as described in Methods ("Analysis of Cancer Cell Lines")  
3) IP-MS Data: Data was processed and analyzed as described in Methods ("Immunoprecipitation and Mass Spectrometry" section; "Database search and data processing" and "Analysis" sub-sections).

#### Data analysis

Code used to apply expectation maximization algorithm to the IP-MS data is available through the Lage Lab website (<http://www.lagelab.org/resources>) and described in Methods ("Immunoprecipitation and Mass Spectrometry" section; "Analysis" sub-section).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Accession codes for RNA-Seq and MS data are as specified in the Methods ("Data Availability Statement").

## Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/authors/policies/ReportingSummary-flat.pdf](https://www.nature.com/authors/policies/ReportingSummary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Statistical methods were not used to predetermine sample size. There was no pre-specified effect size. Sample size for in vitro experiments was comparable to those used in the field. Sample size for in vivo experiments was felt to be reasonable on the basis of the phenotype observed in vitro and also comparable to those used in the field for xenograft experiments.
Data exclusions	For analysis of Project Achilles data, paralog genes were filtered to genes sharing > 25% DNA sequence similarity. In analysis of dependency data, "differentially dependent" genes were filtered to those showing 2sigma differential dependence (shRNA) or using a variance cutoff of 0.01 (CRISPR) as described in Methods ("Analysis of Cancer Cell Lines" section).
Replication	The experiments were reproducible. Additionally, the underlying findings were replicated across multiple cell lines and experimental contexts (i.e. see Fig. 1a-b, Supplemental Tables 1-2).
Randomization	For doxycycline-inducible shRNA xenograft experiments, mice were randomized at 7 days post-injection to match tumor size between groups and one group was started on doxycycline diet.
Blinding	Investigators were not blinded to group allocation.

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
Research sample	State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Sampling strategy	Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Data collection	Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing	Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Non-participation	State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.



## Randomization

If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

## Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

## Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

## Research sample

Describe the research sample (e.g. a group of tagged *Passer domesticus*, all *Stenocereus thurberi* within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

## Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

## Data collection

Describe the data collection procedure, including who recorded the data and how.

## Timing and spatial scale

Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken

## Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

## Reproducibility

Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.

## Randomization

Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.

## Blinding

Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work? ☐ Yes ☐ No

## Field work, collection and transport

## Field conditions

Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).

## Location

State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).

## Access and import/export

Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).

## Disturbance

Describe any disturbance caused by the study and how it was minimized.

## Reporting for specific materials, systems and methods

### Materials & experimental systems

- |                                     |   |
|-------------------------------------|---|
| n/a                                 | Involved in the study   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Unique biological materials            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Antibodies                  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Eukaryotic cell lines       |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology                          |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Human research participants            |

### Methods

- |                                     |  |
|-------------------------------------|--|
| n/a                                 | Involved in the study                              |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq                  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging    |

## Unique biological materials

Policy information about [availability of materials](#)

Obtaining unique materials

*Describe any restrictions on the availability of unique materials OR confirm that all unique materials used are readily available from the authors or from standard commercial sources (and specify these sources).*

## Antibodies

Antibodies used

Catalog numbers for antibodies used in the manuscript are listed in Methods ("Western Blotting", "Immunofluorescence" and "Mouse Experiments" sections).

Validation

Primary antibodies were used at the dilutions specified in Methods ("Western Blotting", "Immunofluorescence" and "Mouse Experiments" sections), which were within the recommended usage range provided by the manufacturers. Antibodies were validated based on staining at the predicted molecular weight or in a pattern reported by manufacturer under standard conditions. For flow cytometry experiments, surface staining was quantified relative to an IgG negative control.

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

Sources of cell lines were as described in Methods ("Cell Culture" section). Briefly, cell line stocks were obtained from the Biological Samples Platform at the Broad Institute and were originally obtained from validated source repositories or academic labs and authenticated prior to use in the Cancer Cell Line Encyclopedia. Original sources for cell lines used were as follows:

1. ChagoK1 - ECACC
2. H460 - ATCC
3. H1437 - ATCC
4. H1373 - ATCC
5. Kuramochi - HSRRB
6. HCC1359 - KCLB
7. HUH1 - HSRRB
8. Heya8 - Academic Lab
9. CHP-212 - ATCC
10. SK-N-DZ - ATCC

Authentication

Cell lines were authenticated in the Biological Samples Platform at the Broad Institute using fingerprint arrays prior to creation of frozen stocks. Additionally, the following cell lines were re-fingerprinted for confirmation using STR profiling after being maintained in culture over the course of the experiments in this manuscript: ChagoK1, H1437, H460.

Mycoplasma contamination

Cell lines were tested for mycoplasma prior to making frozen stocks in Biological Samples Platform. Cell lines were periodically tested for mycoplasma if maintained continuously in culture. No cell lines tested positive for mycoplasma during the course of experiments performed for this manuscript.

Commonly misidentified lines  
(See [ICLAC](#) register)

None

## Palaeontology

Specimen provenance

*Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).*

Specimen deposition

*Indicate where the specimens have been deposited to permit free access by other researchers.*

Dating methods

*If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.*

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

NCR-nude mice, female, 4-5 weeks of age. See also Methods ("Mouse Experiments" section).

Wild animals

Wild animals were not used in this study.

Field-collected samples

Field-collected samples were not used in this study.

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

## ChIP-seq

Data deposition

☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session

(e.g. [UCSC](#))

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Replicates

Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

Peak calling parameters

Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

## Flow Cytometry

Plots

Confirm that:

☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

☐ All plots are contour plots with outliers or pseudocolor plots.

☐ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Cancer cells were cultured using standard techniques and as described in Methods, then collected using enzyme-free dissociation buffer (Gibco, 13151-014), stained, and analyzed.

Instrument

BD LSR Fortessa (custom equipment)

Software

Data were collected using BD FACSDiva software and analyzed using FlowJo v10

Cell population abundance

Cells are a uniform population from cell line culture.

## Gating strategy

Dead cells were excluded based on viability stain, then cells were gated based on FSC and SSC to exclude debris. No other gating was necessary for the uniform cell populations analyzed in this manuscript

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type

Indicate task or resting state; event-related or block design.

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

### Acquisition

Imaging type(s)

Specify: functional, structural, diffusion, perfusion.

Field strength

Specify in Tesla

Sequence &amp; imaging parameters

Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

Area of acquisition

State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.

Diffusion MRI

☐ Used

☐ Not used

### Preprocessing

Preprocessing software

Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).

Normalization

If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

Normalization template

Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

Noise and artifact removal

Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

Volume censoring

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

### Statistical modeling & inference

Model type and settings

Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

Effect(s) tested

Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Specify type of analysis: ☐ Whole brain ☐ ROI-based ☐ BothStatistic type for inference  
(See [Eklund et al. 2016](#))

Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

Correction

Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

### Models & analysis

n/a | Involved in the study

☐ ☐ Functional and/or effective connectivity

☐ ☐ Graph analysis

☐ ☐ Multivariate modeling or predictive analysis



Functional and/or effective connectivity	<i>Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).</i>
Graph analysis	<i>Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).</i>
Multivariate modeling and predictive analysis	<i>Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.</i>